Response of glioblastomas to EGFR kinase inhibitors [4]

New England Journal of Medicine

Volumn 354, Issue 5, 2006, Pages 525-526

  Lassman, Andrew B ^a   Abrey, Lauren E ^a   Gilbert, Mark R ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; TUMOR SUPPRESSOR PROTEIN;

ANALYTIC METHOD; BIOPSY; DRUG RESPONSE; GLIOBLASTOMA; HUMAN; LETTER; OUTCOME ASSESSMENT; PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIVITY ANALYSIS; TREATMENT WITHDRAWAL; VALIDATION PROCESS;

GENE DELETION; GLIOBLASTOMA; HUMANS; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PTEN PHOSPHOHYDROLASE; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 32044436718     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc053459     Document Type: Letter

References (3)

1. Mellinghoff IK, Wang MY, Vivanco I, et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 2005;353:2012-24.
2. Lassman AB, Rossi MR, Razier JR, et al. Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium trials 01-03 and 00-01. Clin Cancer Res 2005;11:7841-50.
3. Lang FF, Gilbert MR, Puduvalli VK, et al. Toward better early-phase brain tumor clinical trials: a reappraisal of current methods and proposals for future strategies. Neuro-oncol 2002;4:268-77.